Table 3.
Variable | Subset | Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|---|
HR (95% CI) 1,2 | p | HR (95% CI) | p | ||
Age (years) | ≥60/<60 | 0.70 (0.34–1.50) | 0.340 | ||
Gender | Male/Female | 1.05 (0.50–2.23) | 0.897 | ||
Body mass index | ≥25/<25 | 0.71 (0.44–1.52) | 0.380 | ||
Smoker | Yes/No | 0.95 (0.43–2.10) | 0.906 | ||
Alcohol | Yes/No | 1.31 (0.44–3.91) | 0.626 | ||
Pre-surgical diabetes | Yes/No | 1.76 (0.83–3.73) | 0.139 | ||
Pre-surgical pancreatitis | Yes/No | 1.00 (0.29–3.37) | 0.994 | ||
Pre-surgical CA.19-9 (U/L) | ≥30/<30 | 1.25 (0.53–2.95) | 0.607 | ||
Pre-surgical CEA (ng/mL) | ≥5/<5 | 0.98 (0.36–2.65) | 0.960 | ||
Pre-surgical bilirubin (mg/dL) | ≥1.2/<1.2 | 1.01 (0.45–2.27) | 0.984 | ||
UICC stage | III-IV/II | 3.27 (1.33–8.05) | 0.010 | 2.97 (1.00–8.88) | 0.051 |
T stage | T3-4/T1-2 | 5.00 (0.40–63.1) | 0.214 | ||
Nodal invasion | N1-2/N0 | 1.71 (0.67–4.38) | 0.263 | ||
Metastasis | M1/M0 | 2.63 (1.23–5.60) | 0.013 | 2.11 (0.85–5.24) | 0.109 |
Grading | G3/G2 | 2.00 (0.59–6.85) | 0.268 | ||
Lymphatic invasion | L1/L0 | 0.96 (0.23–4.06) | 0.956 | ||
Vene invasion | V1/V0 | 2.40 (0.57–10.2) | 0.235 | ||
Resection margin | R1/R0 | 1.61 (0.35–7.31) | 0.540 | ||
Surgery | PPPD 3/left | 4.32 (0.61–30.7) | 0.144 | ||
Chemotherapy | Yes/No | 0.09 (0.02–0.43) | 0.002 | 0.05 (0.01–0.31) | 0.001 |
miR-200b (EpCAM-Exo 4) | High/Low | 2.23 (1.04–4.76) | 0.040 | 2.40 (1.03–5.58) | 0.044 |
miR-200c (S-Exo 5) | High/Low | 2.10 (1.01–4.37) | 0.046 | 0.92 (0.40–2.14) | 0.924 |
Bold values indicate significance (p ≤ 0.05). 1 HR, hazard ratio; 2 CI, confidence interval; 3 PPPD, pylorus-preserving pancreaticoduodenectomy; 4 EpCAM-Exo, EpCAM-positive serum exosomes; 5 S-Exo, total serum exosomes.